The aim of our study was to measure serum concentrations of fibroblast growth factor 19 in patients with obesity (OB), obesity and type 2 diabetes mellitus (T2DM) and healthy subjects (C) at baseline and after selected interventions. We measured serum FGF-19 levels and other biochemical and hormonal parameters in 29 OB and 19 T2DM females and 30 sex-and agematched control subjects. The interventions were acute hyperinsulinemia during isoglycemichyperinsulinemic clamp (n=11 for T2DM and 10 for C), very low calorie diet (VLCD, n=12 for OB) and 3 months treatment with PPAR-α agonist fenofibrate (n=11 for T2DM). Baseline serum FGF-19 levels were significantly lower in OB relative to C group (132.1±12.7 vs. 202.2±16.7 pg/ml, p<0.05), while no significant difference was observed between T2DM and OB or control group.
Introduction
Fibroblast growth factor 19 (FGF-19) is a recently identified endocrine regulator with multiple effects on metabolic processes and energy homeostasis (Itoh and Ornitz 2004; Nishimura et al. 1999; Xie et al. 1999) . Produced predominantly in enterocytes of terminal ileum under the regulation of Farnesoid X receptor (FXR), a bile acid nuclear receptor, and acting mainly in liver through fibroblast growth factor receptor 4 (FGFR4), has been demonstrated to play a central role in the negative feedback loop of bile acid synthesis and gallbladder refilling (Holt et al. 2003; Choi et al. 2006; Inagaki et al. 2005; Yu et al. 2005; Yu et al. 2000) . Animal studies have also shown antiadipogenic, anti-diabetic and hypolipidemic effects of either exogenous administration or endogenous overexpression of FGF-19 with altered expression of a number of genes involved especially in lipid metabolism (Fu et al. 2004; Tomlinson et al. 2002) .
In contrast to animals, only limited data on FGF-19 concentrations, regulation and function are available in humans. In the first study conducted in healthy human volunteers, serum FGF-19 levels exerted a pronounced diurnal rhythm following the rise in serum bile acids, which was abolished upon fasting. Treatment with bile acid sequestrants decreased FGF-19 concentrations, while administration of chenodeoxycholic acid had opposite effect (Lundasen et al. 2006) . In two other studies circulating FGF-19 was found to be increased in patients with end-stage renal disease and extrahepatic cholestasis caused by tumorous obstruction of biliary ducts (Reiche et al.; Schaap et al. 2009 ). Chronically malnourished patients with anorexia nervosa did not show any changes in systemic FGF-19 compared to normal-weight subjects (Dostalova et al. 2008b) . The only two trials exploring in part the relation of FGF-19 to glucose metabolism disorders could not find significant difference in its circulating levels between patients with type 2 diabetes mellitus or insulin resistance relative to healthy controls (Brufau et al. 2010; Schreuder et al. 2010 ).
To our best knowledge, no targeted information about the influence of obesity on circulating FGF-19 levels is available, nor are any data about the dynamic changes in FGF-19 concentrations after dietary intervention or acute hyperinsulinemia. The main regulator of FGF-19 production FXR is an important link between bile acid and triglyceride metabolism, interacting with a variety of genes and receptors, among others PPAR-α (Smelt 2010). The exact role of FGF-19 in these interactions and the influence of lipid-lowering PPAR-α agonists on FGF-19 levels are largely unknown as well. In the present study we therefore addressed the question whether circulating FGF-19 levels are influenced by increased body weight and the presence of T2DM and whether any changes in its concentrations could contribute to positive metabolic effects of very-low calorie diet in patients with obesity or lipid-lowering therapy with PPAR-α agonists in subjects with obesity and type 2 diabetes.
To this end we measured serum FGF-19 concentrations in patients with obesity and T2DM and studied its changes after above mentioned interventions.
Methods

Study subjects and interventions
Overall, 29 women with obesity (defined as BMI ≥ 30) without type 2 diabetes mellitus, 19 women with obesity and type 2 diabetes mellitus and 30 age-matched healthy control women were included into the study. The body weight of all study participants remained stable for at least 3 months before the beginning of the study.
Very low calorie diet sub-study
12 out of 29 obese subjects without type 2 diabetes mellitus underwent a 3-week very low calorie diet (VLCD) program. They were hospitalized in the 3 rd Department of Medicine, General University Hospital, Prague and were given a very low calorie diet with energy content of 2500 kJ/day.
Fenofibrate treatment sub-study 11 obese females with type 2 diabetes mellitus and 10 non-obese women were included into fenofibrate intervention study, which was described in detail elsewhere (Haluzik et al. 2009 ) . T2DM
patients were treated with diet, metformin alone or combination of metformin and glimepiride before the beginning of the study. Diabetic medication remained unchanged from three months before the start throughout the entire study. Diabetic subjects were treated with PPAR-α agonist fenofibrate (Lipanthyl M 267) for three months. Their insulin sensitivity before and after 3 months of fenofibrate treatment was examined by isoglycemic-hyperinsulinemic clamp as described previously (Anderlova et al. 2007) . Ten lean healthy non-diabetic subjects, who were free of any medication, underwent a single isoglycemic-hyperinsulinemic clamp and served as a control group in fenofibrate intervention study.
Written informed consent was signed by all participants before being enrolled into the study. 
Anthropometric examination, blood and tissue sampling
All subjects were measured and weighted and their body mass index (BMI) was calculated. Blood samples were withdrawn between 07:00 h and 08:00 h after overnight fasting. Blood samples were separated by centrifugation for 10 minutes at 1000x g within 30 minutes from blood collection.
Serum was subsequently stored in aliquots at -70 °C until further analysis.
Clinical and hormonal parameters in obese patients on VLCD were measured one day before the beginning of the diet and at the end of the third week of VLCD. Clinical and hormonal parameters in type 2 diabetes patients in the fenofibrate substudy were measured at baseline and after 3 months of treatment with PPAR-α agonist fenofibrate (200mg, Lipanthyl 267M).
Hormonal and biochemical assays
Serum FGF-19 levels were measured by a sandwich enzyme immunoassay (BioVendor, Brno, Czech Republic), following the manufacturer's instructions. Serum samples for FGF-19 measurement were diluted 1:1 with a dilution buffer prior to the assay. The standard curve range for the assay was 15.0 -960.0 ng/ml. Sensitivity was 4.8 pg/ml and the intra-and interassay variability was 3-8 % and 10-13 %, respectively. Serum insulin concentrations were measured by commercial RIA kit (Cis Bio
International, Gif-sur-Yvette Cedex, France). Sensitivity was 2.0 µIU/ml. Serum adiponectin levels were measured by commercial ELISA kit (Linco Research, St. Charles, Missouri, USA). Sensitivity was 0.78 ng/ml. Serum leptin concentrations were measured by commercial ELISA kit (Biovendor, Brno, Czech Republic). Sensitivity was 0.17 ng/ml. The intra-and interassay variability of all kits was less than 5.0 % and 9.0 % respectively.
Biochemical parameters were measured in the Department of Biochemistry of General University
Hospital, Prague by standard laboratory methods. Homeostasis model assessment (HOMA-R) index was calculated as previously described (Matthews et al. 1985) using the following formula:
fasting serum insulin (mIU/l) × fasting serum glucose (mmol/l)/22.5.
Statistical analysis
Statistical analysis was performed using SigmaStat software (SPSS Inc., Chicago, IL). The results are expressed as means ± standard error means (SEM). Changes in FGF-19 and hormonal parameters between studied groups were evaluated by One-way ANOVA followed by Holm-Sidak method or
ANOVA on Ranks followed by Dunn's test and Paired t-test or Wilcoxon Signed Rank Test as
appropriate. Changes of FGF-19 during the clamp were analyzed by One-way RM ANOVA on Ranks followed by Dunn's method. Spearman or Pearson correlation test and multiple regression analysis were used to calculate the relationships between FGF-19 levels and other parameters.
Statistical significance was assigned to p < 0.05.
Results
Baseline characteristics of patients with obesity, patients with type 2 diabetes mellitus and control group
Anthropometric, biochemical and hormonal characteristics of obese, T2DM, and control group are shown in Table 1 . As expected, BMI, blood glucose levels, HOMA index, serum triglyceride, leptin and insulin concentrations were significantly higher in both obese and T2DM group relative to control subjects. On the contrary, adiponectin levels were significantly lower in both of these groups.
No differences in serum cholesterol was found between the groups. When comparing T2DM with obese group, diabetic patients had significantly lower BMI and leptin levels, while blood glucose, triglycerides, insulin and HOMA index were significantly higher in T2DM group relative to obese subjects.
Anthropometric and clinical characteristics of patients included into VLCD study
The influence of VLCD on anthropometric, biochemical and hormonal parameters is summarized in Table 2 . At baseline, patients with obesity had significantly higher BMI, blood glucose, serum insulin, HOMA index and leptin and lower serum adiponectin relative to control subjects. The groups did not significantly differ in serum triglyceride and cholesterol levels. VLCD induced a significant decrease in BMI and HOMA index. Insulin, glucose and leptin concentrations tended to decrease after VLCD, but the difference did not reach the statistical significance. No significant influence of VLCD on serum cholesterol, triglyceride and adiponectin levels was found.
Anthropometric and clinical characteristics of patients included into fenofibrate treatment study
Anthropometric, biochemical and hormonal characteristics of the study sub-group have been described in detail elsewhere (Haluzik et al. 2009 ) and are briefly shown in Table 3 . At baseline, BMI, blood glucose, serum triglyceride, insulin, glycated hemoglobin and atherogenic index were significantly higher, while serum HDL cholesterol was significantly lower in T2DM group relative to control subjects. Three months of treatment with fenofibrate led to a significant decrease of serum triglyceride concentrations, while blood glucose, HOMA index and glycated hemoglobin slightly but significantly increased. Other parameters including BMI were not affected by fenofibrate treatment.
Insulin sensitivity of T2DM group was significantly lower relative to control group and was not affected by fenofibrate treatment (data not shown here, previously described in (Haluzik et al. 2009 ).
The influence of obesity and obesity/type 2 diabetes mellitus on FGF-19 levels and the relationship of FGF-19 levels with anthropometric and metabolic parameters
Circulating concentrations of FGF-19 reached the highest levels in lean control subjects (202.2 ± 16.7 pg/ml), with a non-significant tendency towards lower levels in T2DM group (146.4 ± 15.9 pg/ml) and a further, statistically significant, decrease in the obese non-diabetic group ( Three weeks of very-low calorie diet in our study significantly reduced body weight along with the decrease in blood glucose, insulin and HOMA index and a tendency to improved lipid profile ( Table   2 ). FGF-19 levels tended to increase but the difference did not reach statistical significance. In 
